Compiled all in one place, read news articles from each of the news categories, about drugs, the pharmaceutical industry, national and international awareness causes, scientific meetings, trending stories and epgonline.org headlines.

Site News

Added 7 hours ago Drug news

SUSTAIN 8 and 10 Phase III trials of Ozempic show Ozempic superior in type 2 diabetes.- Novo Nordisk

Novo Nordisk announced the results from two Ozempic (once-weekly semaglutide 1.0 mg) head-to-head Phase III clinical trials, SUSTAIN 8 and...

Added 7 hours ago Drug news

FDA accepts BLA for enfortumab vedotin to treat bladder cancer.- Seattle Genetics.

Seattle Genetics, Inc announced that the FDA has accepted the Biologics License Application (BLA) for the investigational agent enfortumab vedotin...

Added 7 hours ago Drug news

Positive phase III PREVENT trial of Cosentyx to treat non-radiographic axial spondyloarthritis.-Novartis

Novartis, announced positive new data from the PREVENT trial evaluating the efficacy and safety of Cosentyx (secukinumab) in patients with...

Added 7 hours ago Drug news

Alnylam Pharma initiates APOLLO-B phase III trial of Onpattro to treat transthyretin amyloidosis with cardiomyopathy.

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced that the Company has initiated APOLLO-B, a global Phase III placebo-controlled...

Added 2 days ago Drug news

Sanofi and Abbott partner to integrate glucose sensing and insulin delivery technologies to help change the way diabetes is managed

Sanofi and Abbott are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how...

Added 1 day ago Drug news

Tremfya filed with FDA for psoriatic arthritis.- Janssen Pharma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the...

Added 1 day ago Drug news

VP 102 filed with FDA for molluscum contagiosum.- Verrica Pharma

Verrica Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for VP 102 (cantharidin 0.7% Topical Solution), a...

Added 1 day ago Industry news

Lundbeck to acquire Alder Biopharmaceuticals and with it eptinezumab for migraine prevention

H. Lundbeck A/S and Alder BioPharmaceuticals announced a definitive agreement for Lundbeck to acquire Alder. Under the terms of the...

Added 1 day ago Industry news

Purdue Pharma files for bankrupcy

On September 15, 2019 and September 16, 2019, Purdue Pharma L.P. and 23 affiliated debtors (collectively, the "Debtors") each filed...

Added 2 days ago Drug news

Lexicon Pharmaceuticals announced the termination of its alliance with Sanofi for the development and commercialization of Zynquista in both type 1 and type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced the termination of its alliance with Sanofi for the development and commercialization of Zynquista (sotagliflozin) and...

Search all news articles